Ignite Creation Date:
2024-05-06 @ 6:51 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05815108
Status:
RECRUITING
Last Update Posted:
2024-05-17
First Post:
2023-03-08
Brief Title:
Epstein Barr Virus Infection in Patients With Radiologically Isolated Syndrome
Sponsor:
Centre Hospitalier Universitaire de Nice
Organization:
Centre Hospitalier Universitaire de Nice
Study Overview
Official Title:
Prevalence and Prognostic Value of Epstein Barr Virus EBV Infection in Patients With Radiologically Isolated Syndrome RIS
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EBV-RIS
Brief Summary:
The clinical course of RRMS patients is variable Among RIS-Consortium international cohorts one third of RIS patients progressed to MS at 5 years and 522 at 10 years Biomarkers predictive of MS conversion are key elements to organize personalized medical care for both follow-up and treatment strategies EBV seems to be an interesting candidate regarding its involvement MS pathophysiology It can be easily assess in blood sample in contrast to others prognostic biomarkers validated in RIS oligoclonal bands and NfL levels in cerebrospinal fluid and serum In RIS treatment targeting EBV could significantly modify the course of the disease The investigators aim to make the fisrt description of the EBV epidemiology immunoglobulin IgM and IgG anti-viral capsid antigen VCA IgG anti Epstein-Barr nuclear antigen EBNA among RIS patients and to investigate a correlation between the different antibodies titers IgM VCA IgG VCA IgG EBNA and the course of the disease clinical conversion or evidence of disease activity EDA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None